Current Neuro-Oncology
Volume
13 Number 12
31 December 2011
Home > Publications > Current Neuro-Oncology > Volume 13, Year 2011 > Number 12, 31 December
⋆
Abdel-Rahman MH, Pilarski R,
Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P,
Davidorf FH.
Germline
BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma,
meningioma, and other cancers.
J
Med Genet. 2011 Dec;48(12):856-9⍈.
doi: 10.1136/jmedgenet-2011-100156⍈.
Epub 2011 Sep 22. PMID: 21941004⍈.
Laboratory investigation. ⍈
Peyrl
A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T,
Dieckmann K, Schmook MT, Haberler C, Leiss U, Slavc I.
Antiangiogenic
metronomic therapy for children with recurrent embryonal brain
tumors.
Pediatr
Blood Cancer. 2011 Dec 6. 2012;59(3):511-7. doi:
10.1002/pbc.24006⍈.
PMID: 22147459⍈.
Retrospective analysis & Phase 2 trial. ⍈
Radbruch
A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, Bendszus
M.
Relevance
of T2 signal changes in the assessment of progression of
glioblastoma according to the Response Assessment in Neurooncology
criteria.
Neuro
Oncol. 2011 Dec 6. 2012 Feb;14(2):222-9. doi:
10.1093/neuonc/nor200⍈.
PMID: 22146386⍈.
Retrospective
analysis. ⍈
Villano
JL, Letarte N, Bressler LR.
Going
past the data for temozolomide.
Cancer
Chemother Pharmacol. 2011 Dec 7. 2012;69(4):1113-5. doi:
10.1007/s00280-011-1796-4⍈.
PMID: 22147076⍈.
Comment. ⍈
⤷Stupp
R, et al. Effects of radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomised phase III study: 5-year analysis of the EORTC-NCIC
trial.
Lancet
Oncol. 2009 Mar 9. 2009;10(5):459-66. doi:
10.1016/S1470-2045(09)70025-7⍈.
PMID:
19269895⍈.
Phase
3 trial.
⍈
Mason
WP, Macneil M, Kavan P, Easaw J, Macdonald D, Thiessen B, Urva S,
Lwin Z, McIntosh L, Eisenhauer E.
A
phase I study of temozolomide and everolimus (RAD001) in patients
with newly diagnosed and progressive glioblastoma either receiving
or not receiving enzyme-inducing anticonvulsants: an NCIC CTG
study.
Invest
New Drugs. 2011 Dec 9. 2012;30(6):2344-51. doi:
10.1007/s10637-011-9775-5⍈.
PMID: 22160854⍈.
Phase
1 trial. ⍈
Sampson
JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH,
Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA,
Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner
DD, Heimberger AB.
Greater
chemotherapy-induced lymphopenia enhances tumor-specific immune
responses that eliminate EGFRvIII-expressing tumor cells in
patients with glioblastoma.
Neuro
Oncol. 2010 Dec 10. 2011;13(3):324-33. doi:
10.1093/neuonc/noq157⍈.
PMID: 21149254⍈.
Phase 2 trial. ⍈
Nygaard
R, Kivivuori SM.
Treatment
for recurrent medulloblastoma with intrathecal liposomal
cytarabine and systemic metronomic combination therapy.
Anticancer
Drugs. 2011 Dec 12. 2012;23(3):342-6. doi:
10.1097/CAD.0b013e32834ee315⍈.
PMID: 22156796⍈.
Case report. ⍈
McBride
WH.
Integration
of adenovirus thymidine kinase suicide-gene therapy with surgery
and radiation therapy for malignant glioma.
Future
Oncol. 2011 Dec 13. 2012;8(1):17-20.
doi: 10.2217/fon.11.126⍈.
PMID: 22149031⍈.
Comment. ⍈
⤷Chiocca
EA, et al.
Phase IB study of gene-mediated cytotoxic
immunotherapy adjuvant to up-front surgery and intensive timing
radiation for malignant glioma.
J
Clin Oncol. 2011 Aug 15. 2011;29(27):3611-9. doi:
10.1200/JCO.2011.35.5222⍈.
PMID:
21844505⍈.
Phase
1B trial.
⍈
Tsai
HC, Wei KC, Tsai CN, Huang YC, Chen PY, Chen SM, Lu YJ, Lee ST.
Effect
of valproic acid on the outcome of glioblastoma multiforme.
Br
J Neurosurg. 2011
Dec 15. 2012;26(3):347-54. doi: 10.3109/02688697.2011.638996⍈.
PMID: 22168970⍈.
Retrospective
analysis. ⍈
van
Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H,
Vandertop PW, Würdinger T, Noske DP, Kaspers GJ, Cloos J.
PARP
inhibition sensitizes childhood high grade glioma, medulloblastoma
and ependymoma to radiation.
Oncotarget.
2011 Dec 15. 2011;2(12):984-96. doi: 10.18632/oncotarget.362⍈.
PMID: 22184287⍈.
Laboratory investigation. ⍈
Koga
T, Maruyama K, Tanaka M, Ino Y, Saito N, Nakagawa K, Shibahara J,
Todo T.
Extended
field stereotactic radiosurgery for recurrent
glioblastoma.
Cancer.
2011 Dec 16. 2012;118(17):4193-200. doi: 10.1002/cncr.27372⍈.
PMID: 22180028⍈.
Case series. ⍈
Lawrence
YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J,
Shen X, Symon Z, Dicker AP.
Improving
prognosis of glioblastoma in the 21st century: Who has benefited
most?
Cancer.
2011 Dec 16. 2012 Sep 1;118(17):4228-34. doi: 10.1002/cncr.26685⍈.
PMID: 22180310⍈.
Retrospective analysis. ⍈
Murakami
R, Hirai T, Nakamura H, Furusawa M, Nakaguchi Y, Uetani H,
Kitajima M, Yamashita Y.
Recurrence
patterns of glioblastoma treated with postoperative radiation
therapy: relationship between extent of resection and
progression-free interval.
Jpn
J Radiol. 2011 Dec 20. 2012 Apr;30(3):193-7. doi:
10.1007/s11604-011-0031-x⍈.
PMID: 22183828⍈.
Clinical study. ⍈
Zhuang
W, Long L, Zheng B, Ji W, Yang N, Zhang Q, Liang Z.
Curcumin
promotes differentiation of glioma-initiating cells by inducing
autophagy.
Cancer
Sci. 2011 Dec 22. 2012;103(4):684-90. doi:
10.1111/j.1349-7006.2011.02198.x⍈.
PMID: 22192169⍈.
Laboratory investigation. ⍈
Kilickap
S, Oztoprak I, Yucel B.
Complete
remission after bevacizumab plus temozolomide in a patient with
recurrent glioblastoma multiforme.
Acta
Oncol. 2011 Dec 27. 2012;51(4):544-6. doi:
10.3109/0284186X.2011.644251⍈.
PMID: 22201408⍈.
Case report. ⍈